Karios Technologies

What Karios Technologies does

Karios Technologies is a Houston, Texas-based private medical technology company founded in 2020 that develops hydrogel technology intended to prevent postsurgical adhesions and scar tissue formation. The company's core technology addresses a well-documented surgical complication where internal scar tissue forms between tissues and organs following surgery, potentially causing pain, dysfunction, or repeat procedures. With a headcount of 1-10 employees, Karios operates as an early-stage venture focused on the materials science and biomedical engineering of hydrogel-based adhesion barriers.

The company has secured two early-stage funding rounds: a 2021-08-16 round led by the Consortium for Technology & Innovation in Pediatrics, which indicates a deliberate initial focus on pediatric surgical applications, and a 2022-02-01 round involving Reinforced Ventures. These capital sources are consistent with a preclinical or early-clinical development pathway. No FDA approval status, clinical trial milestones, product commercialization timeline, pricing, manufacturing partners, or named customers are disclosed in the available data.

Given the 1-10 employee count, absence of disclosed revenue, and nature of funding sources (including a pediatric technology consortium), Karios appears to be in a pre-commercial R&D phase with the hydrogel platform under development toward eventual regulatory submission and commercialization. No go-to-market channel, distribution model, or revenue mechanics are disclosed at this stage.

Name

Karios Technologies

Website

https://kariostechnologies.com

Company type

Private

Founded year

2020

Headcount range

1–10 employees

Short description

Karios Technologies is a Houston-based early-stage medical device company founded in 2020 that develops hydrogel technology to prevent postsurgical adhesions and scar tissue, initially targeting pediatric surgical applications with a 1-10 person team.

Ownership category

akta.pro rank

Product category

Surgical Adhesion Prevention / Medical Biomaterials

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro industry

PRIMARYHLAAAGAG

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYHLAHALAD

Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

• Hydrogel medical devices
• Postsurgical adhesion prevention
• Surgical scar prevention
• Biomaterials for surgery
• Pediatric surgical devices

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Core offering

Karios Technologies develops hydrogel technology intended to prevent postsurgical adhesions and scar tissue. The company is an early-stage medical device / biomaterials developer focused on hydrogel-based anti-adhesion products for surgical applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Anti-adhesion hydrogel technology Proprietary hydrogel-based biomaterial intended to be applied during surgery to reduce or prevent the formation of postsurgical adhesions and scar tissue. Targeted at hospitals, surgical centers, and surgical specialty practices, with potential applicability to pediatric surgical populations.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• Ethicon (Johnson & Johnson MedTech): Surgical division of J&J MedTech and maker of INTERCEED, one of the leading surgical adhesion barriers. Comparable as the dominant incumbent in the postsurgical adhesion prevention category that Karios would compete against.
• Medline Industries: Major medical products manufacturer and distributor with a broad surgical and wound care portfolio that intersects with hydrogel and adhesion-prevention categories. Comparable as a large-scale incumbent with overlapping surgical supply customers.
• Baxter International: Global medical products company with a portfolio of surgical and adhesion-prevention products (historically including Seprafilm). Comparable as a major incumbent with established surgeon relationships in the adhesion barrier space.
• Atrium Medical Corporation (Getinge): Subsidiary of Getinge developing surgical mesh, vascular grafts, and adhesion prevention products. Comparable as a broader surgical product incumbent with overlapping adhesion barrier offerings.
• Integra LifeSciences: Diversified medical device company with regenerative tissue and surgical products, including wound care and adhesion-related technologies. Comparable as a larger medtech with overlapping surgical hydrogel/regenerative portfolio.

Direct peers

• FzioMed: Privately held developer of Oxiplex, a polymer gel adhesion barrier for spine and abdominal surgery. Closely comparable as a single-product, polymer/hydrogel-based adhesion prevention company.
• Anika Therapeutics: Commercial-stage developer of hyaluronic-acid-based therapies for orthopedic and surgical applications, including products used to prevent adhesions and support post-surgical healing. Directly comparable as a polymer/hydrogel-based surgical adjunct company.
• MAST Biosurgery: Specialty surgical company developing anti-adhesion and sealant products for abdominal and pelvic surgery. Comparable as a focused, smaller competitor in the surgical adhesion prevention category.

Emerging players

• Innocoll Holdings: Specialty surgical company developing collagen-based surgical adhesion barriers. Comparable as a smaller, single-focus peer working on biodegradable/biopolymer adhesion prevention products.
• Carmell Therapeutics: Clinical-stage company developing plasma-based bioactive materials for wound healing and surgical applications. Comparable as an early-stage peer working on novel biomaterial platforms for surgical use.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/karios-technologies-inc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karios Technologies